Moderna's Cancer Trial Data Boosts Stock Amid Oncology Pipeline Hopes
Moderna's stock price has been experiencing volatility, but recent data from its melanoma trial has sparked optimism among investors. The company's intismeran cancer program, a collaboration with Merck, is gaining momentum, reducing uncertainty around its potential and suggesting a clearer regulatory path.
Analysts are taking notice, with Wolfe Research upgrading the stock to Peer Perform and projecting $9.2 billion in peak sales across cancer indications. Barclays has also increased its price target, highlighting the substantial opportunity presented by intismeran, even if it varies by tumor type.
The positive clinical momentum and rising analyst confidence are fueling expectations that Moderna's oncology pipeline could become a major growth engine beyond its COVID franchise. However, the company still faces challenges in broadening its respiratory vaccine portfolio and tightening costs to build a more stable business with recurring demand.